Skip to content
OpenCapital
Get started

Cogent Biosciences, Inc. COGT Research And Development Personnel Related — Operating Income

Other segment segments

Latestage Development
$28.1M0.0%
Other Operational Infrastructure And Advisory Support
$20.22M+184%
Early Stage Preclinical And Discovery Programs
$13.98M+42.9%
Research And Development Software Facilities And Other Strategic Support
$5.73M+29.6%
Depreciation Expense
$626K-2.2%

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHPersonnel And Related Costs — Research And Development Expense
$8.64M+47.7%
Tango Therapeutics logo
TNGXPersonnel-Related Expenses-RD — Research And Development Expense
$12.93M-6.6%
Repligen logo
RGENR&D
$14.46M+19.3%
Kymera Therapeutics logo
KYMRR&D
$98.16M+22.3%
Scholar Rock logo
SRRKR&D
$51.81M+6.4%
LQD
LQDAR&D
$12.57M+80.5%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×—

Profitability

See full
Operating margin-1,044.3%—
Net margin-950.4%—
FCF margin-184.7%—

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity0×-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s research and development personnel related — operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s research and development personnel related — operating income?
Cogent Biosciences, Inc. (COGT) reported research and development personnel related — operating income of $18.05M in Q1 2026.
How has Cogent Biosciences, Inc.'s research and development personnel related — operating income changed year-over-year?
Cogent Biosciences, Inc.'s research and development personnel related — operating income increased by 21.3% year-over-year, from $14.87M to $18.05M.
What is the long-term trend for Cogent Biosciences, Inc.'s research and development personnel related — operating income?
Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s research and development personnel related — operating income has grown at a 34.2% compound annual growth rate (CAGR), from $26.42M to $63.88M.
What does research and development personnel related — operating income mean?
This metric represents the operating loss specifically attributable to personnel-related expenses within the research and development function. It captures the financial impact of human capital investment, including salaries, benefits, and stock-based compensation for staff dedicated to advancing the company's clinical pipeline. Monitoring this figure helps investors assess the cost structure of the company's scientific workforce and the efficiency of its R&D resource allocation.